No Data
Zhijiang Biotech: Zhijiang Biotech: Report for the First Quarter of 2025
Zhijiang Biotech: Report for the first quarter of 2025
Zhijiang Biologics (688317.SH) plans to spend 60 million yuan to -0.12 billion yuan to repurchase shares.
On April 29, Gelonghui reported that Zhijiang Biology (688317.SH) announced that the company plans to repurchase some of its issued ordinary shares (A shares) through a centralized bidding trading method. The repurchased shares are intended to maintain the company's value and Shareholder rights, with the amount for the buyback not less than 60 million yuan (inclusive) and not exceeding 120 million yuan (inclusive), and the repurchase price not exceeding 25.05 yuan per share (inclusive).
Zhejiang Biology's revenue declines in 2024 while losses narrow, the molecular diagnostics Business faces pressure.
① In 2024, Zhijiang Biology's revenue decreased by 34.88% year-on-year, but losses narrowed; ② Revenue from molecular diagnostic instruments fell by 84.01% year-on-year, which significantly impacted the overall performance of the company.
Zhijiang Biotech: Zhijiang Biotech: 2024 Annual Report Summary
Zhijiang Biotech: Zhijiang Biotech: 2024 Annual Report
Some Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) Shareholders Look For Exit As Shares Take 27% Pounding